Antibody-drug conjugate developer Duality Biotherapeutics Inc. debuted on the Hong Kong Stock Exchange (HKEX) with a HK$1.64 billion (US$211.4 million) IPO April 15, making it one of the biggest ...

Affinity Biopharmaceutical Co., Ltd., Shanghai, China.

1Oncology Drug Discovery Unit, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts. *Corresponding Author: Adnan O. Abu-Yousif, Oncology Drug ...

New facility is expected to serve as a global hub for accelerating the development of next-generation antibody-drug conjugates for the treatment of cancer. Boehringer Ingelheim announced the official ...

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting - Zai Lab will highlight potential of ZL-1310 as a promising ...

--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating ZL-1310, the Company’s ...

and an alkaline phosphatase (AP)-conjugated mouse anti-FITC antibody (Roche 11426338910). Spots of antibody secreting cells were revealed by adding in the dark the HRP substrate AEC kit (Vectro ...

The emergence of antibody–drug conjugates (ADCs) shows promise for treating a variety of tumours by using target-specific monoclonal antibodies to deliver cytotoxic substances directly to cancer cells ...